Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

诺泽 - NMPA Drug Approval Details

Approvals/NMPA/Recombinant Human Somatropin Injection

Approved

生物制品

Recombinant Human Somatropin Injection

Novo Nordisk A/S🇨🇳 National Medical Products Administration

Approval Date: Nov 21, 2019
Approval ID: 7ucmdfKML1R
Company: Novo Nordisk A/S
Type: 生物制品

Approval Details

Approval Id: 7ucmdfKML1R
Approval Number: 国药准字J20190028
Generic Name: 人生长激素注射液
Generic Name En: Recombinant Human Somatropin Injection
Trade Name: 诺泽
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 1.5ml:5mg(NordiFlex)
Reg Date: 2019-11-21
Company Name: Novo Nordisk A/S
Company Address: Novo Alle 1, DK-2880 Bagsvaerd, Denmark
Production Company Name: Novo Nordisk A/S
Production Company Address: Novo Alle 1, DK-2880 Bagsvaerd, Denmark
Company Detail Path: /organization/novo-nordisk-a-s
Production Company Detail Path: /organization/novo-nordisk-a-s

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Nov 21, 2019

Approval ID

7ucmdfKML1R

Type

生物制品

Back to NMPA Approvals